Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023
19 Luglio 2023 - 3:00PM
Artelo Biosciences,
Inc.
(Nasdaq: ARTL), a
clinical-stage pharmaceutical company focused on modulating
lipid-signaling pathways to develop treatments for people living
with cancer, pain, and neurological conditions, today announced
that Saoirse O’Sullivan, PhD, Vice President of Translational
Sciences at Artelo Biosciences, will be presenting “The Therapeutic
Potential of Fatty Acid Binding Protein (FABP) Inhibitors” at the
Gordon Research Conference on “Charting the Course to Novel
Therapeutics From a Fundamental Understanding of Cannabinoid
Neurobiology” being held July 16-21, 2023 at the Rey Don Jaime
Grand Hotel in Spain.
https://www.grc.org/cannabinoid-function-in-the-cns-conference/2023/
“I am looking forward to sharing our data on the potential
applications of inhibiting fatty acid binding proteins from our
extensive library of compounds,” said Professor O’Sullivan. “We are
particularly excited to share new information on the effects of our
FABP inhibitor ART26.12 on not only cannabinoid receptors, but
other receptors implicated in pain signaling, as well as lipidomic
and transcriptome data that help us understand how ART26.12 elicits
its effects in peripheral neuropathies.”
Professor O’Sullivan’s presentation on Thursday, July 20, 2023
includes data on ART26.12, Artelo’s lead compound targeting a
variety of painful neuropathies, as well as the potential of FABP
inhibitors beyond peripheral neuropathies. ART26.12 was selected
from Artelo’s platform of inhibitors to FABPs as its first
candidate drug. The Company recently announced it expects pre-IND
meeting feedback on its IND planning and development strategy from
the Food and Drug Administration during the third quarter of this
year with the goal of initiating clinical development in early
2024.
About ART26.12Fatty Acid Binding Proteins
(FABPs) are a family of intracellular proteins that chaperone
lipids including endocannabinoids and fatty acids. Various
inhibitors of FABPs may be particularly useful for the treatment of
specific cancers, neuropathic and nociceptive pain, and anxiety
disorders. ART26.12, Artelo’s lead FABP inhibitor compound, is a
selective inhibitor of FABP5. While developing ART26.12 in painful
neuropathies, including for CIPN, the Company has additional
compounds from an extensive library of potent and selective
inhibitors of FABPs that have been identified and selected for
advancement towards regulatory-enabling studies in cancer and other
areas of high-unmet need where inhibition of FABPs show significant
promise. Artelo’s extensive library of FABP inhibitors is protected
with three patents issued in the United States and 14 pending
patent applications.
About Artelo BiosciencesArtelo Biosciences,
Inc. is a clinical stage pharmaceutical company dedicated to
the development and commercialization of proprietary therapeutics
that modulate lipid-signaling pathways including the
endocannabinoid system. Artelo is advancing a portfolio of broadly
applicable product candidates designed to address significant unmet
needs in multiple diseases and conditions, including anorexia,
cancer, anxiety, pain, neuropathy, and inflammation. Led by proven
biopharmaceutical executives collaborating with highly respected
researchers and technology experts, the company applies leading
edge scientific, regulatory, and commercial discipline to develop
high-impact therapies. More information is available
at www.artelobio.com and Twitter: @ArteloBio.
About the Gordon Research
Conference
The Cannabinoid Function in the CNS GRC is a
premier, international scientific conference focused on advancing
the frontiers of science through the presentation of cutting-edge
and unpublished research, prioritizing time for discussion after
each talk and fostering informal interactions among scientists of
all career stages. The conference program includes a diverse range
of speakers and discussion leaders from institutions and
organizations worldwide, concentrating on the latest developments
in the field.
Forward Looking StatementsThis press release
contains certain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 and Private Securities Litigation
Reform Act, as amended, including those relating to the Company’s
product development, clinical and regulatory timelines, market
opportunity, competitive position, possible or assumed future
results of operations, business strategies, potential growth
opportunities and other statement that are predictive in nature.
These forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management’s current beliefs and
assumptions. These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
“expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,”
“potential,” “predict,” “project,” “should,” “would” and similar
expressions and the negatives of those terms. These statements
relate to future events and involve known and unknown risks,
uncertainties, and other factors which may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Such factors include those set
forth in the Company’s filings with the Securities and Exchange
Commission, including our ability to raise additional capital in
the future. Prospective investors are cautioned not to place undue
reliance on such forward-looking statements, which speak only as of
the date of this press release. The Company undertakes no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise,
except to the extent required by applicable securities laws.
Investor Relations Contact:Crescendo
Communications, LLCTel:
212-671-1020Email: ARTL@crescendo-ir.com
Grafico Azioni Artelo Biosciences (NASDAQ:ARTL)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Artelo Biosciences (NASDAQ:ARTL)
Storico
Da Mag 2023 a Mag 2024